Chasteberry

(Vitex agnus-castus)t

 

Clinical Studies
References


Chasteberry is used for rheumatic conditions, body inflammation and swelling, menstrual irregularities, symptoms of menopause and symptoms of premenstrual syndrome (PMS), amongst others. The applicable part of the chasteberry tree is the fruit. It has anti-inflammatory activity, especially due to the main active ingredient, agnuside, which has COX-2 inhibiting activity.

Other therapeutic effects of chasteberry have been attributed to its indirect effects on various neurotransmitters and hormones. Chasteberry seems to affect dopamine, and possibly acetylcholine and opioid receptors too. Preliminary research suggests chasteberry might have analgesic and antihistaminic activity. Preliminary research suggests it also might have estrogen and progestin activity. Chasteberry appears to be selective for beta estrogen receptors. The beta estrogen receptor predominates in the heart, vasculature, bone and bladder. Chasteberry doesn't affect testosterone levels in men.

 

 

Published Clinical Studiescl top

Iridoids with Anti-Inflammatory Activity from Vitex peduncularis1

A. Suksamrarn1, S. Kumpun1, K. Kirtikara2, B. Yingyongnarongkul1, S. Suksamrarn3

 

1 1 Department of Chemistry, Ramkhamhaeng University, Bangkok, Thailand 2 2 National Centre for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Bangkok, Thailand 3 3 Department of Chemistry, Srinakharinwirot University, Bangkok, Thailand

Abstract

A new iridoid, pedunculariside, together with the known iridoid agnuside were isolated from the butanol extract of Vitex peduncularis stem bark. Both pedunculariside and agnuside showed preferential inhibition of COX-2, with IC50 values of 0.15 ± 0.21 mg/ml and 0.026 ± 0.015 mg/ml respectively, while having only small inhibitory effects on COX-1. Both compounds did not exhibit cytotoxicity against vero cells.

 

back

Pharmacological activities of Vitex agnus-castus extracts in vitro.2

Meier B, Berger D, Hoberg E, Sticher O, Schaffner W.

 

Zeller AG, Herbal Medicinal Products, Romanshorn, Switzerland. beat.meier@zellerag.ch

The pharmacological effects of ethanolic Vitex agnus-castus fruit-extracts (especially Ze 440) and various extract fractions of different polarities were evaluated both by radioligand binding studies and by superfusion experiments. A relative potent binding inhibition was observed for dopamine D2 and opioid (micro and kappa subtype) receptors with IC50 values of the native extract between 20 and 70 mg/mL. Binding, neither to the histamine H1, benzodiazepine and OFQ receptor, nor to the binding-site of the serotonin (5-HT) transporter, was significantly inhibited. The lipophilic fractions contained the diterpenes rotun-difuran and 6beta,7beta-diacetoxy-13-hydroxy-labda-8,14-dien . They exhibited inhibitory actions on dopamine D2 receptor binding. While binding inhibition to mu and kappa opioid receptors was most pronounced in lipophilic fractions, binding to delta opioid receptors was inhibited mainly by a aqueous fraction. Standardised Ze 440 extracts of different batches were of constant pharmacological quality according to their potential to inhibit the binding to D2 receptors. In superfusion experiments, the aqueous fraction of a methanolic extract inhibited the release of acetylcholine in a concentration-dependent manner. In addition, the potent D2 receptor antagonist spiperone antagonised the effect of the extract suggesting a dopaminergic action mediated by D2 receptor activation. Our results indicate a dopaminergic effect of Vitex agnus-castus extracts and suggest additional pharmacological actions via opioid receptors.

PMID: 11081988 [PubMed - indexed for MEDLINE]

 

back to top

Referencesre

  1. Leung AY, Foster S. Encyclopedia of Common Natural Ingredients Used in Food, Drugs and Cosmetics. 2nd ed. New York, NY: John Wiley & Sons, 1996.
  2. McGuffin M, et al, ed. American Herbal Products Association's Botanical Safety Handbook. Boca Raton, FL: CRC Press, 1997.
  3. Brinker F. Herb Contraindications and Drug Interactions. 2nd ed. Sandy, OR: Eclectic Medical Publications, 1998.
  4. Eagon PK, Elm MS, Hunter DS, et al. Medicinal herbs: modulation of estrogen action. Era of Hope Mtg, Dept Defense; Breast Cancer Res Prog, Atlanta, GA 2000;Jun 8-11.
  5. Mills S, Bone K. Principles and Practice of Phytotherapy. London: Churchill Livingstone, 2000.
  6. Cahill DJ, Fox R, Wardle PG, et al. Multiple follicular development associated with herbal medicine. Hum Reprod 1994;9:1469-70.
  7. McCaleb RS, Leigh E, Morien K. The Encyclopedia of Popular Herbs. Roseville, CA: Prima Health, 2000.
  8. Du Mee C. Vitex agnus castus. Aust J Med Herb 1993;5:63-5.
  9. Brown D. Vitex agnus castus clinical monograph. Qtrly Rev Natural Med 1994;2:111-21.
  10. Wuttke W. Dopaminergic action of extracts of Agnus Castus. Forschende Komplementarmedizen 1996;3:329-30.
  11. Jarry H, Leonhardt S., Gorkow C, Wuttke W. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus Castus: direct evidence for a dopaminergic principle by the dopamine receptor assay. Exp Clin Endocrinol 1994;102:448-54.
  12. Merz P, Gorkow C, Schroder A, et al. The effects of a special Agnus castus extract (BP1095el) on prolactin secretion in healthy male subjects. Exp Clin Endocrinol Diabetes 1996;104:447-53.
  13. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomized, placebo-controlled study. Br Med J 2001;322:134-7.
  14. Lauritzen CH, Reuter HD, Repges R, et al. Treatment of premenstrual tension syndrome with Vitex agnus castus: Controlled-double blind versus pyridoxine. Phytomedicine 1997;4:183-9.
  15. Gerhard II, Patek A, Monga B, et al. Mastodynon for female infertility. Forsch Komplementarmed 1998;5:272-8.
  16. Berger D. Schaffner W, Schrader E, et al. Efficacy of Vitex agnus castus L. extract Ze 440 in patients with premenstrual syndrome (PMS). Arch Gynecol Obstet 2000;264:150-3.
  17. Loch EG, Selle H, Boblitz N. Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus castus. J Womens Health Gend Based Med 2000;9:315-20.
  18. Milewicz A, Gejdel E, Sworen H, et al. [Vitex agnus castus extract in the treatment of luteal phase defects due to latent hyperprolactinemia. Results of a randomized placebo-controlled double-blind study]. [Article in German]. Arzneimittelforschung 1993;43:752-6.
  19. Dixon-Shanies D, Shaikh N. Growth inhibition of human breast cancer cells by herbs and phytoestrogens. Oncol Rep 1999;6:1383-7.
  20. Ohyama K, Akaike T, Hirobe C, Yamakawa T. Cytotoxicity and apoptotic inducibility of Vitex agnus-castus fruit extract in cultured human normal and cancer cells and effect on growth. Biol Pharm Bull 2003;26:10-18.
  21. Upton R, ed. Chaste Tree Fruit. American Herbal Pharmacopoeia and Therapeutic Compendium. Santa Cruz, CA; American Herbal Pharmacopoeia. 2001:1-37.
  22. Meier B, Berger D, Hoberg E, et al. Pharmacological activities of Vitex agnuscastus extracts in vitro. Phytomedicine 2000;7:373-381.
  23. Liu J, Burdette JE, Xu H, et al. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem 2001;49:2472-9.